Citable filing context
MO's research view summarizes recent SEC filing context, starting with earnings from Jul 30, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 30, 2026 | earnings | Altria reported Q2 2026 financial results and narrowed its full-year 2026 adjusted diluted EPS guidance to $5.61-$5.72. |
| May 18, 2026 | management_change | Altria appointed Salvatore Mancuso as CEO and Heather Newman as CFO, while former CEO William Gifford Jr. retired. |
| Apr 30, 2026 | earnings | Altria reported Q1 2026 adjusted diluted EPS of $1.32, up 7.3%, and reaffirmed full-year guidance. |
| Jul 30, 2026 | Guidance: adjusted_diluted_eps | 5.61 to 5.72 |
| Jul 30, 2026 | Guidance: capital_expenditures | 375.00 to 450.00 |
| Apr 30, 2026 | Guidance: adjusted diluted EPS | 5.56 to 5.72 |
| Jul 30, 2026 | mda_quarterly | Altria’s financial performance for the first half of 2026 reflects a focus on its "Moving Beyond Smoking" vision, characterized by a transition toward smoke-free products despite ongoing macroeconomic and regulatory headwinds. The company reported net revenues of $11.5 billion for the six-month period, a 1.6% increase year-over-year, driven primarily by its smokeable products segment. However, domestic cigarette shipment volumes declined by an estimated 4.5% (adjusted for trade inventory), as adult nicotine consumers increasingly shift toward discount brands and innovative smoke-free alternatives. Key operational developments include the "Optimize & Accelerate" initiative to modernize processes and the "USSTC Facilities Consolidation" in Kentucky, which incurred $78 million in charges during the first half of 2026. The company’s e-vapor segment, centered on NJOY, remains a focal point of regulatory and legal scrutiny, particularly regarding patent litigation with JUUL and the impact of illicit flavored disposable e-vapor products on market dynamics. Altria maintains significant equity investments in Anheuser-Busch InBev (ABI) and Cronos Group, which continue to influence earnings through equity method accounting and market-related adjustments. While the company faces persistent litigation risks and stringent FDA oversight, it remains committed to its 2028 Enterprise Goals and capital allocation strategies, including share repurchases and dividend payments. |
| Apr 30, 2026 | mda_quarterly | Altria Group reported a significant increase in Q1 2026 net earnings to $2.18 billion and diluted EPS to $1.30, primarily driven by higher operating income compared to the prior year which included a substantial non-cash impairment of e-vapor goodwill. Adjusted net earnings rose 6.2% to $2.22 billion, and adjusted diluted EPS increased 7.3% to $1.32, benefiting from higher operating companies income and fewer shares outstanding. The smokeable products segment saw net revenues increase 2.9% due to pricing gains, despite a 4% adjusted domestic cigarette shipment volume decline, influenced by macroeconomic pressures pushing consumers to discount brands. Marlboro maintained a 59.5% premium segment share. The oral tobacco products segment experienced a 2.3% net revenue increase, with higher pricing offsetting an 8.5% adjusted shipment volume decline. While the overall U.S. nicotine pouch category grew significantly, Altria's on! brand saw its share of the nicotine pouch category decrease to 13.4%. Key risks include ongoing litigation, particularly the ITC exclusion order impacting NJOY ACE e-vapor products, and the slower-than-anticipated enforcement against illicit e-vapor products, which continues to pressure the e-vapor reporting unit's goodwill valuation. The company maintains $3.5 billion in cash and has $720 million remaining on its share repurchase program, having repurchased $280 million in Q1. |
Source: SEC EDGAR filing text and events; period Jul 30, 2026; filed Jul 30, 2026.
MO company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.